Sanofi (NASDAQ:SNY) Shares Sold by Cresset Asset Management LLC

Cresset Asset Management LLC decreased its stake in Sanofi (NASDAQ:SNY - Free Report) by 88.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,058 shares of the company's stock after selling 44,579 shares during the period. Cresset Asset Management LLC's holdings in Sanofi were worth $292,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of SNY. Synergy Asset Management LLC acquired a new position in Sanofi during the 4th quarter worth approximately $25,000. McClarren Financial Advisors Inc. lifted its position in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after purchasing an additional 543 shares in the last quarter. Lee Danner & Bass Inc. purchased a new position in shares of Sanofi in the fourth quarter valued at $31,000. Bessemer Group Inc. boosted its stake in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after purchasing an additional 242 shares during the period. Finally, Sierra Ocean LLC purchased a new position in Sanofi in the fourth quarter valued at about $44,000. Hedge funds and other institutional investors own 14.04% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on SNY shares. The Goldman Sachs Group started coverage on Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 target price for the company. BNP Paribas started coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Finally, Hsbc Global Res raised Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Sanofi has a consensus rating of "Buy" and a consensus price target of $63.33.

Sanofi Stock Performance

SNY traded up $0.60 on Monday, hitting $52.28. 1,500,928 shares of the company's stock were exchanged, compared to its average volume of 2,377,379. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock has a fifty day moving average of $53.25 and a two-hundred day moving average of $51.88. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The firm has a market cap of $132.07 billion, a PE ratio of 21.00, a P/E/G ratio of 1.01 and a beta of 0.55.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The business had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. During the same quarter in the previous year, the firm posted $1.78 EPS. The business's revenue for the quarter was down 11.0% compared to the same quarter last year. On average, research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. This represents a yield of 3.1%. This is a positive change from Sanofi's previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. Sanofi's payout ratio is presently 57.14%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.